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A B S T R A C T
Objectives: Fibromyalgia (FM) is a generalized chronic pain syndrome of unknown aetiology. Although FM
patients frequently complain of cognitive dysfunction, this is one of the least studied symptoms. Research on
brain activity associated with the perceived cognitive impairment is particularly scarce. To address this gap, we
recorded the brain electrical activity in participants during a cognitive control task.
Methods: Electroencephalograms (EEGs) were recorded in 19 FM patients and 22 healthy controls (all women)
while they performed the Multi-Source Interference Task (MSIT). We analyzed the amplitude of the frontal N2
and parietal P3 components elicited in control and interference trials and their relation with reaction times. We
also explored the relationship of perceived cognitive dysfunction, assessed using visual analogue scales (VAS)
and the Memory Failures of Everyday (MFE-30) test, with N2 and P3 amplitudes.
Results: The N2 amplitudes were smaller in FM patients than in controls and were negatively associated with
cognitive complaints. Unlike patients, healthy controls showed significant differences in the amplitude of P3
obtained from control vs. interference trials of the MSIT. Smaller N2 and P3 amplitudes were associated to longer
reaction times.
Conclusions: The findings suggest a reduction in frontal brain activity during performance of an interference
task, which was associated with the patients' cognitive complaints. Findings on P3 suggest altered modulation of
attention according to the task demands in FM patients. Deficits in flexibility in the allocation of attentional
resources and cognitive control during complex tasks may explain the dyscognition reported by chronic pain
patients.
1. Introduction
Fibromyalgia (FM) is a chronic pain syndrome of unknown ae-
tiology and complex, variable evolution. This syndrome has an esti-
mated prevalence in developed countries of between 1% and 4%,
mainly affecting women (Alegre Martín, 2008). FM is characterized by
widespread pain, constant tiredness and non-restorative sleep, but one
of its most distinctive, and also rarely examined, symptoms is cognitive
dysfunction. Although cognitive impairment has been reported in the
50% of the FM patients (Katz et al., 2004), the neural basis of such
alterations is not clear.
Several studies have investigated the incidence of cognitive dys-
function in chronic pain syndromes, particularly in FM (Glass and Park,
2001). Most research efforts have focused on attention and memory
processes, in which FM patients rather consistently show poorer per-
formance than healthy controls (Grace et al., 1999; Glass and Park,
2001; Park et al., 2001; Dick et al., 2002; Dick et al., 2008; Cherry et al.,
2009; Berryman et al., 2013; Landrø et al., 2013; Gelonch et al., 2016).
Nevertheless, some reports failed to confirm cognitive deficits in FM
patients performing neuropsychological tests of attention and memory
(Suhr, 2003; Walitt et al., 2008; Glass et al., 2011; Walitt et al., 2016).
Executive functions, including processes such as planning, attention,
cognitive flexibility, inhibition or decision making, have been much less
studied in FM patients. In 2014, Berryman et al. conducted a meta-
analysis of 22 studies and reported that in patients with chronic pain
there is a small impairment of executive function evaluated in a com-
plex way, a result that the authors explain by the large variability of the
tests used in the studies (Berryman et al., 2014). In view of the in-
consistencies, some authors argue that the cognitive complaints made
by FM patients are disproportionate to the actual performance dis-
played (Grace et al., 1999; Suhr, 2003; Castel et al., 2008; Schmidt-
Wilcke et al., 2010) or may be explained by depression symptoms
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(Gelonch et al., 2016; Gelonch et al., 2017; Ojeda et al., 2017).
Regarding cognitive dysfunction and chronic pain, it has been
proposed that pain captures attention and consumes part of the patient's
attentional resources, thus impairing cognitive functioning (Eccleston
and Crombez, 1999; Landrø et al., 2013; Tesio et al., 2015). This ex-
planation is supported by neuroimaging studies that have assessed
brain activity associated with higher cognitive processes, such as ex-
ecutive functioning in FM patients. Glass et al. (2011) observed lower
activation in areas related to both pain perception and executive
functioning in FM patients performing a Go-No Go task. Similarly, Seo
et al. (2012) reported hypoactivation in the dorsolateral prefrontal
cortex (DLPFC), the ventrolateral prefrontal cortex and the inferior
parietal cortex in FM patients performing an n-back working memory
task. Moreover, Schmidt-Wilcke et al. (2014) reported an increase in
the activity of the anterior and middle cingulate cortex during the Go-
No Go task in patients with reduced pain levels. These authors sug-
gested that pain reduction may favour the availability of neural re-
sources for other functions, such as inhibition. According to this con-
cept, a hyperactive pain system, brought about by ongoing pain
perception/anticipation/vigilance, takes up neural resources which are
then no longer available for other networks and/or leads to poor in-
tegration of other brain networks in the pain system, and subsequently
to their malfunctioning (Schmidt-Wilcke et al., 2014).
Although the analysis of brain electrical activity of FM patients
while they perform cognitive tasks may be useful to clarify the existence
of deficits in cognitive control and/or reduced allocation of attentional
resources during executive functioning, studies conducted so far have
used simple tasks such as the oddball paradigm. Using this task, it has
been found that the amplitude of the N2 and P3 components of event-
related potentials (ERPs) is smaller in FM patients than in controls
(Ozgocmen et al., 2003; Yoldas et al., 2003; Alanoğlu et al., 2005). The
smaller N2 amplitude has been interpreted as a deficit in executive
control (Nieuwenhuis et al., 2003), including conflict and error mon-
itoring and the ability to cancel a prepared response (Botvinick et al.,
2004). On the other hand, the smaller P3 amplitude has been inter-
preted as an indicator of a reduced amount of attentional resources
devoted to task execution (Folstein and Van Petten, 2008). Although
these results seem to be consistent with attention deficit in FM, studies
analyzing EEGs recorded during tasks that specifically assess processes
such as executive control are scarce.
The overall objective of this study was to clarify the neural basis of
dyscognition in FM by comparing the EEGs recorded in FM patients and
healthy controls while they performed the Multi-Source Interference
Task (MSIT), a task that activates the cognitive/attentional network.
The MSIT, originally designed to elicit a robust interference effect in
neuroimaging studies (Bush et al., 2003), has been widely used to study
interference control in the healthy population and in numerous clinical
conditions (Bush et al., 2003; Bush and Shin, 2006; Bush et al., 2008;
Shehzad et al., 2012,; Veldhuijzen et al., 2012; Bush et al., 2013; Mao
et al., 2014; Huerta-Albarrán et al., 2015; González-Villar et al., 2017).
Previous fMRI studies in healthy individuals have shown that the MSIT
activates the dorsal anterior midcingulate cortex, the DLPFC, premotor
areas and parietal regions (Bush et al., 2003). These areas correspond to
the cingulate-fronto-parietal network, which plays a critical role in at-
tention and cognitive processing (Bush and Shin, 2006). In this study,
we examined the N2 and P3 components of the ERPs and put them in
relation to objective indices of performance (reaction times) and sub-
jective cognitive complaints. We hypothesized that patients will show
poorer MSIT performance along with smaller N2 and P3 amplitudes.
Moreover, we expected to observe a negative relationship between
subjective cognitive complaints and the N2 and P3 amplitudes.
2. Materials and methods
Nineteen patients with FM (mean age 43.58 ± 7.52) and twenty-
two healthy controls (HCs) (mean age 45.14 ± 7.26), all right-handed,
participated in the study. One FM participant was excluded due to in-
adequate performance of the task. The data included here are part of a
larger study, and the patients' characteristics and behavioural results on
task performance have already been described (González-Villar et al.,
2017). The groups were matched by sex (all women), age and years of
education (see Table 1). All FM patients had a previous diagnosis ac-
cording to the ACR (1990) criteria by a primary care physician or
rheumatologist, and had no other disease that could explain generalized
pain. Furthermore, all patients included in the study reported moderate
(often present) or severe (constantly present, life-disturbing) cognitive
problems in the Symptom Severity Score of the Fibromyalgia Survey
Questionnaire (Wolfe et al., 2011). Exclusion criteria for the FM group
were the presence of neurological and psychiatric diseases (except de-
pression or anxiety, since these two disorders show a high comorbidity
with FM: see Aguglia et al., 2011), or history of substance abuse. The
same exclusion criteria were applied to the control participants, who in
addition, should not suffer from chronic pain problems.
The participants were advised not to smoke or consume coffee, al-
cohol or other non-prescribed drugs before the evaluation; however,
they were not asked to change their consumption of medically pre-
scribed treatments. All participants had normal or corrected vision.
Each participant was paid 25 euros to cover travel expenses.
The experimental procedure was approved by the research ethics
committee of the University of Santiago de Compostela and all the
participants were informed about the experiment and have signed in-
formed consent before participation.
2.1. Clinical assessment
2.1.1. Fibromyalgia symptoms assessment
2.1.1.1. Fibromyalgia survey Questionnaire. We used the Spanish version
of the Fibromyalgia Survey Questionnaire (FSQ) (Carrillo-de-la-Peña
Table 1
Descriptive statistics of the scales used and demographic variables, for fibromyalgia patients (FM) and healthy controls (HC).
Variable FM (n= 18) mean (SD) HC (n= 22) mean (SD) t p Cohen's d
Age 43.9 (7.6) 45.1 (7.2) −0.5 p=0.61 –
Years of education 10.4 (3.5) 11.3 (3.3) −0.8 p=0.42 –
Symptom Severity Scale (SSS) 9.8 (2.3) 2.5(2.3) 10.0 p < 0.001 3.17
Widespread Pain Index (WPI) 14.0 (4.8) 1.7 (1.8) 10.2 p < 0.001 3.39
VAS. Pain 7.7 (2.0) 1.4 (1.6) 11.0 p < 0.001 3.47
VAS. Health status 7.6 (2.3) 2.3 (2.7) 6.7 p < 0.001 2.11
VAS. Mood status 7.4 (2.9) 2.9 (2.3) 5.4 p < 0.001 1.71
VAS. Functional affectation 8.2 (2.4) 0.1 (0.3) 15.4 p < 0.001 4.73
VAS. Non-restorative sleep 8.6 (2.1) 2.1 (2.4) 8.4 p < 0.001 2.88
VAS. Attention 6.9 (1.7) 2.2 (2.0) 7.9 p < 0.001 2.53
VAS. Memory 8.0 (1.8) 2.6 (2.1) 8.5 p < 0.001 2.76
VAS. Concentration 7.6 (1.9) 2.5 (2.4) 7.3 p < 0.001 2.35
Memory failures of everyday (MFE-30) 73.2 (22.5) 20.6(13.9) 8.9 p < 0.001 2.81
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et al., 2015) originally published by Wolfe et al. (2011) and based on
the diagnostic criteria proposed by Wolfe et al. (2010) with a self-report
format. It includes a Symptom Severity Scale (SSS), which considers
three key symptoms in FM: fatigue, cognitive problems (attention,
concentration or memory) and non-restorative sleep. The FSQ also
encompasses other symptoms such as abdominal pain, depression and
headache. It also includes a Widespread Pain Index (WPI) indicating the
number of body areas with pain reported by the patient.
2.1.1.2. Visual-analogue scales. We used a series of Visual-Analogue
Scales (VAS), which were created ad-hoc to evaluate the clinical status
of participants. The scales consist of a set of horizontal 10 cm-long lines
along which participants were asked to indicate their status for the
following variables: pain, health status, mood, interference of their
health in daily activities and non-restorative sleep. Also, we used VAS
to assess subjective complaints regarding memory, attention and
concentration during the last month. All scales were presented so that
the right end indicated the worst condition and the left, the best.
2.1.1.3. Memory failures of everyday (MFE-30) test. To assess memory
problems, we used the Spanish validation of the modified Memory
Failures of Everyday questionnaire (MFE-30) (Lozoya-Delgado et al.,
2012) originally reported by Sunderland et al. (1984). The MFE-30,
which evaluates memory lapses in everyday life, consists of a 30-items
questionnaire with Likert responses (0: never or almost never, 1: rarely;
2: sometimes yes and sometimes not, 3: often, 4: always or almost
always). In addition to subjective memory problems, the questionnaire
evaluates other cognitive complaints related to perception, linguistics
and praxical process.
3. Procedure and task
The questionnaires described above were first administered to the
participants. For the EEG recording session, the participants sat in a
comfortable chair in a dimly lit room isolated from external sounds.
Each participant was fitted with an electrode cap and conductive paste
was applied at each electrode to achieve the desired impedances.
During the task, the participants were asked to look steadily at a
point in front of them and to avoid moving their eyes and muscles. The
MSIT instructions were clearly explained and all participants conducted
10 practice trials before performing the task. Participants had to re-
spond via a response box with the index (1), middle (2) or ring (3)
finger of their dominant hand to the different number of a series of
three numbers displayed on the screen; they should respond to the
identity of the different number and avoid responding to its position
(see Fig. 1). In the control condition, the position of the different
number was congruent with the response finger and was accompanied
by zeros (i.e., “100”, “020”, “003”). In the interference condition, the
position of the different number was incongruent with the response
finger and was accompanied by two different numbers from 1 to 3 (i.e.,
“221”, “212”, “331”, “313”, “112”, “211”, “332”, “233”, “131”, “311”,
“232” and “322”). The proportion of trials was 50% for each condition
(50% control trials; 50% interference trials). The trials were presented
randomly, although there were no more than three consecutive trials of
the same condition or with the same response finger. Each stimulus was
presented for 900ms, with a random inter-stimulus interval (ISI) be-
tween 1700 and 2200ms. Responses were recorded in the interval 150
to 2500ms after the start of stimulus presentation. A total of 400 sti-
muli were presented to each participant. The task was designed and
presented using PsychoPy (Peirce, 2009), on a 17-in. screen located
80 cm from the subject (See Fig. 1).
3.1. EEG recording and processing
The EEGs were recorded using the actiCHamp system (Brain
Products Inc.), via 62 electrodes placed according to the 10–20
International System. The reference electrode was placed at the tip of
the nose and the ground in the FPz position. Four additional surface
electrodes were placed 1 cm above and below of the right eye and in the
lateral canthus of both eyes to monitor vertical and horizontal ocular
movements. Electrode impedances were kept below 10 KΩ. The EEG
was digitized at 500 Hz and filtered with a 0.1–100 Hz on-line band
pass filter and a 50 Hz Notch filter.
The EEG data were analyzed using the EEGlab v.3.13 toolbox
(Delorme and Makeig, 2004). The EEGs were re-referenced to an
average reference. EEG segments with artefacts were manually rejected
after visual inspection. Data were digitally filtered using a 0.5 Hz high
pass filter and a 30 Hz low-pass filter. We extracted epochs from 800ms
pre-stimulus to 1800ms post-stimulus. An Independent Component
Analysis (ICA) algorithm was used to remove the components asso-
ciated with ocular or muscular activity. In three participants, one
electrode had to be removed due to high levels of noise, and then re-
constructed using spherical-spline interpolation. To obtain the ERPs,
correctly responded epochs were averaged separately for control and
interference trials, and baseline correction was applied from −200 to
0ms. We selected two Regions of Interest (ROI) to measure N2 and P3
ERPs. For each participant, the N2 amplitude was computed as the
mean voltage from 250 to 320ms at the electrodes FC1, FCz, FC2 and
Cz; while P3 amplitude was computed as the mean voltage from 350 to
600ms at the electrodes P1, Pz, P2 and POz. These latency windows
and electrodes were selected because they show the highest modulation
of the N2 and P3 components.
3.2. Data analysis
The FM and HC groups were compared in relation to socio-demo-
graphic values, SSS, WPI, VAS, MFE data and behavioural results (re-
action times and hits) using t-tests for independent samples. Repeated-
measures ANOVAs were conducted for N2 and P3 amplitudes, with
Condition (control vs. interference) as the within-subject factor and
Group (FM vs. HC) as the between-subject factor. When the sphericity
assumption was not fulfilled, Greenhouse-Geisser correction was used
to determine the significance levels. When the ANOVA indicated that a
factor was significant, t-tests with the Bonferroni correction were used
in the post-hoc comparisons.
We also performed linear regression to analyze to what extent N2
and P3 amplitudes predicted reactions times, considering separately
control and interference trials. Effect size analyses were undertaken to
Fig. 1. MSIT task. The subjects had to respond to the different number in the
series, with their index (1), middle (2) or ring (3) fingers. During the control
trials, the distractor stimuli were zeros (0) and the target number was placed in
the position congruent with its position on the response box where the parti-
cipant should respond. During interference trials, distractors were other num-
bers (1, 2 or 3) and the target was never placed in a position congruent with the
position in the response box. In the first example the correct answer would be to
press the “1” button with the index finger; and in the second example the
correct answer would be to press the “2” button with the middle finger.
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assess the magnitude of differences between groups in clinical vari-
ables. Specifically, Cohen's d was computed for t-tests, partial eta-
squared [ηp2] for ANOVAs, and Cohen's ƒ2 for linear regressions. Finally,
Pearson's correlations were computed, only for the sample of FM pa-
tients, to evaluate associations between N2 and P3 amplitude and
cognitive complaints (MFE-30 and VAS for memory, attention and
concentration). All statistical analyses were performed with SPSS v. 20
(SPSS Inc., Chicago, IL, USA).
4. Results
Demographic and behavioural data were reported in a previous
paper (González-Villar et al., 2017). There were no differences between
groups in terms of age or education level. The results of the clinical
assessment showed significant differences (p < 0.001) within FM pa-
tients and HCs in all the variables considered, with higher scores for
patients with FM. These significative differences showed a Cohen's d
superior to 0.80 for all the clinical measures, indicating a large effect
size for the clinical variables (See Table 1). Regarding the behavioural
performance of the MSIT, the reaction times (RT) were significantly
slower in FM patients than in healthy controls. There were no group
differences for the proportion of correct responses. Effect size analyses
for the RT showed a large effect and the hit's effect size analyses for the
control condition showed a medium effect, however for the interference
condition showed a small effect (see Table 2).
For the N2 amplitude, the ANOVA revealed significant main effects
for Group (F(1,38) = 4.34; p= 0.04, ηp2= 0.10) and Condition
(F(1,38) = 6.23; p=0.02, ηp2= 0.14); these effect sizes are considered
as medium and large, respectively. The amplitude of this component
was smaller in FM patients, and larger for the control than for the in-
terference condition. The Group x Condition interaction was not sig-
nificant (F(1,38) = 0.50 p=0.48, ηp2= 0.01).
For the P3 amplitude, the ANOVA showed significant effects for
Condition (F(1,38)= 29.64; p < 0.001, ηp2= 0.44) and for the Group x
Condition interaction (F(1,38) = 7.21; p= 0.01, ηp2= 0.16); both effect
sizes are large. Post-hoc comparisons showed significantly larger P3
amplitudes to control than interference trials for the HCs (p < 0.001),
while the difference was not significant for the patients (p= 0.071).
(See Table 3, Fig. 2).
To analyze the association between ERPs amplitudes and reaction
times we performed linear regression analyses. The results show that
the amplitude of N2 and P3 at control and interference conditions
significantly predicted the reaction times of the participants (See
Table 4). The effect size analysis for the linear regression of reaction
times in the control condition showed a large effect (ƒ2= 0.57), while
for the interference condition it showed a medium effect (ƒ2= 0.16).
In FM patients, N2 amplitude was significantly correlated with at-
tention, memory and concentration (assessed by VAS). Smaller N2
amplitudes were associated with larger self-perceived cognitive dys-
function (See Table 5).
5. Discussion
The main aim of this study was to understand the neural mechan-
isms involved in the cognitive dysfunction reported by FM patients. To
this end, we recorded EEGs in FM patients and healthy controls while
they performed the Multi-Source Interference Task (MSIT), a test de-
signed to explore processes related to attentional control and inter-
ference processing. We examined the frontal N2 and parietal P3 com-
ponents of the ERPs and correlated them with indices of subjective
cognitive complaints.
According to our hypotheses concerning neural activity related to
the performance of the MSIT, we found a decrease in N2 amplitude in
FM patients. The N2 component has been interpreted as a neural cor-
relate of conflict detection and monitoring, necessary for the response
program updating and successful inhibition (Huster et al., 2013). Thus,
the smaller N2 amplitudes found in the patients may indicate their
lower involvement in the processing of the task stimuli. This finding is
in line with previous research on spontaneous brain activity and EEG
time-frequency analyses in FM patients. Several studies have shown
altered patterns of spontaneous brain activity in the patients (like in-
creased connectivity between the default mode network and other
cortical structures), suggestive of a dominance of endogenous top-down
influences that may be limiting the processing of incoming stimuli
(Ceko et al., 2015; Ichesco et al., 2014). Using time-frequency analyses,
we observed lower theta activity in patients than in controls during the
performance of the MSIT (González-Villar et al., 2017). As the theta
frequency band has been related to N2 and is also considered an in-
dicator of conflict monitoring and response competition (Müller and
Anokhin, 2012), the similar results found using different markers of
brain activity lend greater robustness to our findings.
The N2 wave has a fronto-central scalp distribution and its neural
basis has been located in the dorsal portion of the anterior cingulate
cortex (ACC), a brain structure involved in monitoring the concurrent
and competitive coactivation of responses or stimuli representations
(Van Veen and Carter, 2002; Botvinick et al., 2004). A previous neu-
roimaging study reported less activation of the ACC in chronic pain
patients while they were performing the MSIT, suggesting that this
region plays a major role in the cognitive dysfunction (Mao et al.,
2014). Thus, our results are also consistent with previous neuroimaging
findings obtained using the MSIT with FM and chronic pain patients.
Against our expectations and contrary to previous findings using the
oddball task (Ozgocmen et al., 2003; Yoldas et al., 2003; Alanoğlu et al.,
2005), we were not able to confirm a general reduction in the ampli-
tude of the P3 component in FM patients. We used a specific task to
assess cognitive control and observed different patterns of brain elec-
trical activity across trials: healthy controls showed larger P3 amplitude
in control than interference trials, while the patients did not show
significant modulation. The smaller P3 amplitudes in the interference
condition may be explained by its increased difficulty, as compared to
Table 2
Means, SD (Standard Deviations), and t-tests of the behavioural data: RTs (Reaction Times, in milliseconds) and hits (percentage) for control and interference trials of
the Multi-Source Interference Task (MSIT).
FM mean (SD) HC mean (SD) t p Cohen's d
RT Control 809.34 (149.12) 681.92 (122.92) 2.96 p < 0.01 0.93
interference 1116.45 (206.34) 946.40 (144.08) 3.06 p < 0.01 0.96
Hits Control 97.40% (3.37) 99.05% (1.83) −1.85 p= 0.07 0.61
Interference 87.19% (16.30) 91.59% (6.91) −1.14 p= 0.25 0.35
Table 3
Mean N2 and P3 amplitudes and SD (Standard Deviations).
FM HCs










1.71 (5.53) 0.59 (6.58) 3.87 5.57) 0.57 (5.66)
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the control one. Given that the temporo-parietal component P3 has
been considered an index of attentional processing of the target sti-
mulus (Polich, 2007), our findings suggest that FM patients may not use
appropriate strategies to solve the task, assigning similar amounts of
attentional resources to stimuli processing in both, control and inter-
ference conditions.
Altogether, the decrease in the amplitude of frontal N2 and the lack
of difference in the P3 amplitude across trials suggest that patients with
FM may have difficulty in modulating attention according to the task
demands. This pattern of neural activity may explain the poorer be-
havioural performance of the patients in the MSIT; in fact, smaller N2
and P3 amplitudes successfully predicted longer reaction times.
Previous studies have also reported slower reactions times and larger
number of errors in the patients (Veldhuijzen et al., 2012; González-
Villar et al., 2017).
In this study we attempted to relate the brain activity recorded
during the MSIT to the cognitive symptoms reported by the patients.
There is some discussion regarding the nature of cognitive complaints
by chronic pain patients and whether they are disproportionate or ob-
jective (Grace et al., 1999; Gervais et al., 2001; Suhr, 2003; Walitt et al.,
2016; Gelonch et al., 2017). With the aim of obtaining a more accurate
measure of cognitive symptoms, we used both Visual-Analogue Scales
(VAS) and the Memory Failures of Everyday questionnaire (MFE-30).
Considering the cognitive profile of the patients included in the study,
our evaluations confirmed the presence of a moderate to severe dys-
function in attention, memory and concentration in the FM group.
According to our hypothesis, in FM patients, we found significant cor-
relations between N2 amplitude and complaints about attention,
memory and concentration, with smaller amplitudes indicating greater
cognitive dysfunction. These results suggest a link between a poor in-
volvement in the task (i.e. reduced monitoring of stimuli) and greater
subjective impression of dyscognition. In line with our results, Walitt
et al. (2016) reported that subjective complaints of FM patients corre-
late with a decrease in BOLD response (in supramarginal gyrus/primary
somatosensory cortex, posterior insula, left inferior temporal cortex, left
inferior parietal cortex and bilateral occipital cortex) during the ex-
ecution of a working memory task (n-back). Moreover, other studies
have also reported correlations between the self-reported complaints
and objective performance indices of cognition capacity (Park et al.,
2001; Leavitt and Katz, 2006; Verdejo-García et al., 2009; Landrø et al.,
2013; Tesio et al., 2015).
The above findings can be interpreted following the hypothesis that
cognitive processes- such as attention, inhibition or cognitive control,
and pain perception depend on overlapping networks (Eccleston and
Crombez, 1999; Landrø et al., 2013; Tesio et al., 2015). It is known that
both painful stimuli and cognitive tasks (n-back, MSIT, go/no-Go, etc)
robustly activate regions in the prefrontal cortex and superior parietal
lobes, as well as the ACC, mid-cingulate cortex (MCC), supplementary
motor area, and the anterior insular cortex (Schmidt-Wilcke et al.,
2014). In chronic pain patients, the constant processing of pain may use
up neural resources that may be necessary to perform tasks that require
attentional load, thus affecting cognitive processing (Eccleston and
Fig. 2. Left- Regions of Interest (ROIs) used to measure N2 (FC1, FCz, FC2 and Cz electrodes) and P3 (P1, Pz, P2 and POz). Center- Event related potentials obtained
for the Fibromyalgia (FM) and Healthy Control (HC) groups in control and interference trials of the MSIT. The shaded areas show the time windows used to measure
the mean amplitude of the ERPs. Right- The scalp distributions of the components for both groups and conditions.
Table 4
Linear regression results (standardized beta coefficient) for Reaction Times (RT;
dependent variable) using N2 and P3 amplitude in both conditions of the task







N2 0.463 (p= 0.001) 0.481 (p= 0.010)
P3 −0.570 (p < 0.001) −0.415 (p= 0.025)
Table 5
Pearson r correlations of the Visual-Analogue Scales (VAS) and Memory Failures of Everyday (MFE-30) score, with N2 and P3 obtained in MSIT control and
interference trials, for FM patients.
VAS Attention r (p) VAS memory r (p) VAS concentration r (p) MFE-30 r (p)
N2 control 0.620 (p= 0.006) 0.613 (p=0.007) 0.744 (p < 0.001) 0.361 (p= 0.141)
N2 interference 0.541 (p= 0.021) 0.566 (p=0.014) 0.696 (p=0.001) 0.298 (p= 0.230)
P3 control 0.147 (p= 0.560) −0.091 (0.718) 0.093 (p=0.714) −0.210 (p= 0.402)
P3 interference 0.188 (p= 0.454) 0.015 (p=0.954) 0.224 (p=0.371) −0.109 (p= 0.667)
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Crombez, 1999; Glass et al., 2011; Seo et al., 2012; Schmidt-Wilcke
et al., 2014). Nevertheless, there is some controversy about this idea,
because the interactions between pain and cognition are poorly defined.
Some researchers have observed poorer performance of patients with
FM in neuropsychological tests of attention and memory (Glass and
Park, 2001; Park et al., 2001; Dick et al., 2002, 2008; Landrø et al.,
2013; Tesio et al., 2015; Gelonch et al., 2016; Ojeda et al., 2017) and
cognitive control tasks (Verdejo-García et al., 2009; Cherry et al., 2012;
Berryman et al., 2013; Gelonch et al., 2016), while others have not
(Suhr, 2003; Glass et al., 2011; Walitt et al., 2016). The discrepancies
between studies may stem from the different nature of the tests used to
assess cognitive abilities, differences in the samples and other metho-
dological issues.
We acknowledge some limitations of our study. First, the medica-
tion taken by the patients may have affected the results. Although
participants were instructed to not consume more medication than
necessary, for ethical reasons we did not asked them to discontinue
prescribed medication. Many of the patients were taking anxiolytic and
antidepressant drugs that may affect the Central Nervous System, and
therefore the electrophysiological indices. In addition, some partici-
pants reported suffering insomnia and distress, which may also affect
the findings. Furthermore, it should be noted that we used a version of
the MSIT (random presentation of control and interference trials) that
deviates from the standard presentation in blocks, and that may also
have affected the results obtained. The inclusion of simple control trials
between the more difficult interference trials may partly explain the
higher amplitude of P3 in the control condition, a result that is at odds
with our previous report (González-Villar et al., 2017). Moreover, the
sample of this study was exclusively composed of women. Although FM
is a syndrome suffered mostly by female (Wolfe et al., 1995), this aspect
presents a limitation in our study in terms of its generalization to the
male population. Future research should also establish whether the
susceptibility of FM patients to suffer from cognitive deficits can be
explained by the presence of other symptoms such as pain or depres-
sion.
In conclusion, FM patients and healthy controls were significantly
different in brain electrical activity indices obtained during the MSIT
that were related to the behavioural performance of the task. The data
on the P3 component suggests that patients may have difficulty in
modulating the number of attentional resources needed to perform
activities with varying cognitive loads. We also found that the sub-
jective cognitive dysfunction reported by the patients is related to an
objective, neural index (N2 amplitude). Taken together, the N2 and P3
results allow us to better understand the cognitive dysfunction reported
by FM patients: a poor stimuli monitoring may lead to less cognitive
flexibility and worse performance in tasks that require cognitive con-
trol. Simple tasks may not be sensitive enough to bring out the patient's
dyscognition, thus explaining some of the inconsistencies in previous
literature. Besides, these findings provide evidence in favour of the
hypothesis of some overlap between networks involved in pain and
executive function, thus helping to explain why patients with chronic
pain may develop cognitive problems. Finally, the results provide
knowledge that may improve the diagnosis and treatment of these pa-
tients: the use of brain electrical activity biomarkers could help to
characterize the patients' dyscognition and stablish profiles to design
more individualized treatment strategies.
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